FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Staffing Shortages are Lengthening Trial Planning

[ Price : $8.95]

An industry consultant says reduced FDA staffing levels and high turnover are extending regulatory timelines and forcing drug deve...

Kennedy Ally Says Makary Blocking Covid Shot Withdrawal

[ Price : $8.95]

Axios reports that the vice chair of the CDC Advisory Committee on Immunization Practices says the Pfizer and Moderna Covid mRNA v...

FDA Annual Report on CDRH International Harmonization

[ Price : $8.95]

CDRH reports on its 2025 MDUFA 5 activities to promote international harmonization.

Suggestions to Revise Hatch-Waxman Skinny Label Provisions

[ Price : $8.95]

A Congressional Research Service backgrounder explains options Congress could consider to resolve some issues with the skinny labe...

Summit BLA for Lung Cancer Therapy

[ Price : $8.95]

FDA accepts for review a Summit Therapeutics BLA seeking approval for ivonescimab in combination with chemotherapy in patients wit...

FDA Politicization Depth and Breadth Unprecedented: Professor

[ Price : $8.95]

University of Southern California public policy professor Genevieve Kanter airs concerns about the impact of the many changes that...

FDA Denies Ozempic Petition Without Substantive Comment

[ Price : $8.95]

Faced with a legal deadline for a response, FDA denies without comment on the specifics a law firms petition seeking restrictions ...

124 Novel Medical Devices Authorized in 2025: Report

[ Price : $8.95]

The CDRH 2025 annual report says the Center authorized 124 novel medical devices last year, one of the highest numbers of authoriz...

2 Regenxbio Gene Therapies Get Clinical Holds

[ Price : $8.95]

FDA places clinical holds on two Regenxbio investigational gene therapy programs for ultra-rare pediatric diseases following the i...

Boehringer Ingelheim Reports Data on Kidney Drug

[ Price : $8.95]

Boehringer Ingelheim says its investigational kidney drug apecotrep reduced proteinuria by 40% compared with placebo in a Phase 2 ...